logo-loader
viewAbzena PLC

Abzena CEO on the potential for acquisitions and reaching profitability

John Burt, the chief executive of Abzena (LON:ABZA), discusses the company’s business model, the busy period of newsflow ahead, and the potential for acquisitions.

While profitability may be a few years away yet, Burt says there are already a few products in the clinic that the company will be able to earn royalties from.

The company raised £20 million in last July’s IPO, which Burt says ‘gives a good platform for the future because our business model doesn’t require a lot of capital because we’re not funding clinical trials’.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tiziana Life Sciences files patent application for its novel coronavirus...

Tiziana Life Sciences (LON:TILS) chairman and founder Gabriele Cerrone talks Proactive London's Andrew Scott through the company's update this morning which he describes as an important step in finding a solution to the current pandemic. It's filed a patent around the direct delivery method of...

17 minutes ago

2 min read